Deadline: 23-Nov-2025
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is offering funding opportunities for innovative, patient-centered clinical trials that have the potential to improve the lives of cancer patients.
The foundation supports interventional clinical trials from Phase I to Phase III that focus on optimizing therapies, reducing disease and treatment burden, and advancing early detection and intervention. The emphasis is on delivering real, timely impact for patients, and not on supporting basic research, observational studies, or projects with commercial revenue goals.
Applicants must hold a doctoral degree and have a faculty or equivalent appointment at an academic or research institution. Both early-career and established independent investigators are encouraged to apply, provided they have the experience to manage a clinical trial and ensure the protection and welfare of participants. The foundation welcomes applications from international teams and places no restrictions on cancer type or geographical location. However, typically only one active grant is allowed per grantee at a time.
Eligible projects must be interventional clinical trials and include meaningful involvement of patient partners. If this component is not yet established, applicants can apply for a pre-application grant to develop this aspect. Trials can involve generic or academic-developed drugs, while on-patent drugs will only be considered in cases involving rare cancers with no treatment alternatives. Clinical trials involving immunotherapy should be discussed with the foundation before applying. Pediatric cancer trials are also eligible, particularly those testing innovative, less toxic treatments or representing high-risk, high-reward approaches.
The foundation is also interested in studies that aim to detect or intervene in early or precancerous stages of cancer, with preference given to trials targeting high-risk populations. These applications must include preliminary data showing a strong link between the proposed method and the cancer type and should demonstrate that the method is owned by the applying institution or investigator. Projects focused on population-wide screening or companion diagnostics are not eligible.
RTFCCR typically provides up to USD 100,000 per year for the duration of the clinical trial, for a maximum of five years. The funding is milestone-driven and can be used for non-reimbursable patient care costs, study-related expenses, personnel salaries, and specific equipment used exclusively for the funded project. The foundation requires regular reporting and participation milestones to ensure ongoing disbursement of funds.
This grant presents a valuable opportunity for clinical researchers aiming to develop and implement impactful cancer treatments and interventions, with a strong focus on patient benefit and scientific integrity.
For more information, visit RTFCCR.
